CA2140814A1 - Utilisation de calreticuline pour la modulation de la receptivite hormonale et nouveaux produits pharmaceutiques servant au traitement du cancer, de l'osteoporose et des maladies inflammatoires chroniques - Google Patents

Utilisation de calreticuline pour la modulation de la receptivite hormonale et nouveaux produits pharmaceutiques servant au traitement du cancer, de l'osteoporose et des maladies inflammatoires chroniques

Info

Publication number
CA2140814A1
CA2140814A1 CA 2140814 CA2140814A CA2140814A1 CA 2140814 A1 CA2140814 A1 CA 2140814A1 CA 2140814 CA2140814 CA 2140814 CA 2140814 A CA2140814 A CA 2140814A CA 2140814 A1 CA2140814 A1 CA 2140814A1
Authority
CA
Canada
Prior art keywords
calreticulin
receptor
hormone
proteins
product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2140814
Other languages
English (en)
Inventor
Shoukat Dedhar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA 2140814 priority Critical patent/CA2140814A1/fr
Publication of CA2140814A1 publication Critical patent/CA2140814A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/4359—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from fleas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Insects & Arthropods (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
CA 2140814 1995-01-23 1995-01-23 Utilisation de calreticuline pour la modulation de la receptivite hormonale et nouveaux produits pharmaceutiques servant au traitement du cancer, de l'osteoporose et des maladies inflammatoires chroniques Abandoned CA2140814A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA 2140814 CA2140814A1 (fr) 1995-01-23 1995-01-23 Utilisation de calreticuline pour la modulation de la receptivite hormonale et nouveaux produits pharmaceutiques servant au traitement du cancer, de l'osteoporose et des maladies inflammatoires chroniques

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA 2140814 CA2140814A1 (fr) 1995-01-23 1995-01-23 Utilisation de calreticuline pour la modulation de la receptivite hormonale et nouveaux produits pharmaceutiques servant au traitement du cancer, de l'osteoporose et des maladies inflammatoires chroniques

Publications (1)

Publication Number Publication Date
CA2140814A1 true CA2140814A1 (fr) 1996-07-24

Family

ID=4155095

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2140814 Abandoned CA2140814A1 (fr) 1995-01-23 1995-01-23 Utilisation de calreticuline pour la modulation de la receptivite hormonale et nouveaux produits pharmaceutiques servant au traitement du cancer, de l'osteoporose et des maladies inflammatoires chroniques

Country Status (1)

Country Link
CA (1) CA2140814A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999005172A2 (fr) * 1995-01-24 1999-02-04 Shoukat Dedhar Produits pharmaceutiques permettant de moduler la capacite de reponse aux hormones
WO2000020577A1 (fr) * 1998-10-06 2000-04-13 The Government Of The United States Of America, Represented By The Secretary, Dept. Of Health And Huuman Services, The National Institutes Of Health Utilisation de la calreticuline et de fragments de la calreticuline pour inhiber la croissance des cellules endotheliales et l'angiogenese, et supprimer la croissance tumorale
WO2002006327A2 (fr) * 2000-07-17 2002-01-24 Northwestern University Procede de pronostic du cancer et proteines utilisees
US6426220B1 (en) 2000-10-30 2002-07-30 Isis Pharmaceuticals, Inc. Antisense modulation of calreticulin expression
US6518397B1 (en) 1997-07-24 2003-02-11 Shoukat Dedhar Pharmaceuticals for modulating hormone responsiveness
US6596690B2 (en) 1998-10-06 2003-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vasostatin as marrow protectant
US6867180B1 (en) 1998-10-06 2005-03-15 The United States Of America As Represented By The Department Of Health And Human Services Use of calreticulin and calreticulin fragments to inhibit endothelial cell growth and angiogenesis, and suppress tumor growth

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999005172A2 (fr) * 1995-01-24 1999-02-04 Shoukat Dedhar Produits pharmaceutiques permettant de moduler la capacite de reponse aux hormones
WO1999005172A3 (fr) * 1995-01-24 1999-04-15 Shoukat Dedhar Produits pharmaceutiques permettant de moduler la capacite de reponse aux hormones
US6518397B1 (en) 1997-07-24 2003-02-11 Shoukat Dedhar Pharmaceuticals for modulating hormone responsiveness
WO2000020577A1 (fr) * 1998-10-06 2000-04-13 The Government Of The United States Of America, Represented By The Secretary, Dept. Of Health And Huuman Services, The National Institutes Of Health Utilisation de la calreticuline et de fragments de la calreticuline pour inhiber la croissance des cellules endotheliales et l'angiogenese, et supprimer la croissance tumorale
US6596690B2 (en) 1998-10-06 2003-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vasostatin as marrow protectant
US6867180B1 (en) 1998-10-06 2005-03-15 The United States Of America As Represented By The Department Of Health And Human Services Use of calreticulin and calreticulin fragments to inhibit endothelial cell growth and angiogenesis, and suppress tumor growth
US7432236B2 (en) 1998-10-06 2008-10-07 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Vasostatin as marrow protectant
US7488711B2 (en) 1998-10-06 2009-02-10 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of calreticulin and calreticulin fragments to inhibit endothelial cell growth and angiogenesis, and suppress tumor growth
US7812117B2 (en) 1998-10-06 2010-10-12 The United States Of America As Represented By The Department Of Health And Human Services Vasostatin as marrow protectant
WO2002006327A2 (fr) * 2000-07-17 2002-01-24 Northwestern University Procede de pronostic du cancer et proteines utilisees
WO2002006327A3 (fr) * 2000-07-17 2003-06-26 Univ Northwestern Procede de pronostic du cancer et proteines utilisees
US6426220B1 (en) 2000-10-30 2002-07-30 Isis Pharmaceuticals, Inc. Antisense modulation of calreticulin expression

Similar Documents

Publication Publication Date Title
US5854202A (en) Peptide fragments of calreticulin, peptide mimetics thereof, and pharmaceutical compostions comprising same
Dedhar et al. Inhibition of nuclear hormone receptor activity by calreticulin
Porter et al. Role of estrogen receptor/Sp1 complexes in estrogen-induced heat shock protein 27 gene expression.
Zhang et al. A nuclear receptor corepressor modulates transcriptional activity of antagonist-occupied steroid hormone receptor
Liu et al. EGR-1, the reluctant suppression factor
Fujimoto et al. Alteration in the agonist/antagonist balance of antiestrogens by activation of protein kinase A signaling pathways in breast cancer cells: antiestrogen selectivity and promoter dependence.
Takahata et al. Transactivation mechanisms of mouse clock transcription factors, mClock and mArnt3
Van den Berghe et al. FIF [fibroblast growth factor-2 (FGF-2)-interacting-factor], a nuclear putatively antiapoptotic factor, interacts specifically with FGF-2
Schreiber et al. The estrogen-related receptor (ERR) functions in PPAR coactivator 1 (PGC-1)-induced mitochondrial biogenesis
Maroder et al. Cell-specific bifunctional role of Jun oncogene family members on glucocorticoid receptor-dependent transcription.
El Shafey et al. Inhibition of the myostatin/Smad signaling pathway by short decorin-derived peptides
US5786362A (en) Method of treating Hormone independent cancer
Foletta et al. Cloning of rat ARHGAP4/C1, a RhoGAP family member expressed in the nervous system that colocalizes with the Golgi complex and microtubules
AU2001281232A1 (en) The anti-neoplastic agent ET-743 inhibits trans activation by SXR
CA2140814A1 (fr) Utilisation de calreticuline pour la modulation de la receptivite hormonale et nouveaux produits pharmaceutiques servant au traitement du cancer, de l'osteoporose et des maladies inflammatoires chroniques
US6518397B1 (en) Pharmaceuticals for modulating hormone responsiveness
US20030124508A1 (en) Method for testing the hormonal effect of substances
Yanase et al. Modification of Androgen Receptor Function by Igf‐1 Signaling: Implications in the Mechanism of Refractory Prostate Carcinoma
WO1999005172A2 (fr) Produits pharmaceutiques permettant de moduler la capacite de reponse aux hormones
Wang et al. Synleurin, a novel leucine-rich repeat protein that increases the intensity of pleiotropic cytokine responses
Uhler et al. The Nk-2 box of the Drosophila homeodomain protein, Vnd, contributes to its repression activity in a Groucho-dependent manner
Montminy et al. Regulation of somatostatin gene transcription by cAMP
CA2443676A1 (fr) Modulateur nouveau d'activite non genomique de recepteurs nucleaires (mnar) et applications connexes
FUKAWA et al. Homologous down-regulation of the glucocorticoid receptor down-modulates cellular hormone responsiveness in human histiocytic lymphoma U937 cells
AU4586199A (en) New pharmaceuticals for modulating hormone responsiveness

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead